Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis.

By Y. Tham, Xiang Li, Tien Yin Wong, H. Quigley, T. Aung, Ching-Yu Cheng. Ophthalmology (Rochester, Minn.), 2014

6,813 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/99ed082846edf7e6fc626a0108a56c3286dc6a94

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Ji-Peng Olivia Li
Hanruo Liu
D. S. Ting
S. Jeon
R. Chan
Judy E. Kim
Dawn Sim
Deepkumar Patel

Citations in the corpus

Efficacy of a Deep Learning System for Detecting Glaucomatous Optic Neuropathy Based on Color Fundus Photographs. (2018, background): “As a result of population growth and ageing, this figure is expected to increase to 112 million by 2040.(3) Most vision loss resulting from glaucoma is avoidable through early detection and treatment strategies.”
Epidemiology of Glaucoma: The Past, Present, and Predictions for the Future (2020, background): “PACG is further classified into acute (closure of anterior chamber angle with a sudden increase in IOP) and chronic (closure of the anterior chamber angle with a gradual increase in IOP or development of peripheral anterior synechiae) [1].”
REFUGE Challenge: A Unified Framework for Evaluating Automated Methods for Glaucoma Assessment from Fundus Photographs (2019, neutral): “itives. vCDR: Vertical Cup-to-Disc Ratio. 1. Introduction Glaucoma is a chronic neuro-degenerative condition that is one of the leading causes of irreversible but preventable blindness in the world (Tham et al., 2014). In 2013, 64.3 million people aged 40-80 years were estimated to suer from glaucom”
Digital technology, tele-medicine and artificial intelligence in ophthalmology: A global perspective (2020, background): “…pressure (IOP), retinal ganglion cell death, loss of visual field (VF) and eventual vision loss (Weinreb et al., 2014) and is the main cause of irreversible blindness, affecting ~64.3 million patients aged from 40 to 80 years worldwide (Stevens et al., 2013; Bourne et al., 2013; Tham et al., 2014).”